HEIDELBERG, Germany — It’s been a rough year for Lion Bioscience

In January, its long-reigning CEO Friedrich von Bohlen resigned. Then, in June, the company’s high-profile collaboration with Bayer expired, and last week, Lion’s two co-CEOs and entire supervisory board stepped down.

But Thure Etzold, Lion’s newly appointed chief technology officer, said that the most recent changes in upper management won’t have any impact on the company’s product-development plans.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.